LEO Pharma appoints new Chief Financial Officer and Executive Vice President
18.8.2022 15:32:19 CEST | LEO Pharma | Press release
Philip joins LEO Pharma from Topsoe where he has been CFO since November 2020. Previously, he was CFO at Atos Medical and before that held various leadership positions with Coloplast, including Regional CFO, North America & Pacific. Philip brings extensive experience across finance, strategy and M&A and has a proven track record of driving business transformation.
Philip has a management consulting background from Bain & Company and attained his M.Sc. in Finance and Accounting from Copenhagen Business School and University of Michigan’s Ross Business School.
“I am confident that Philip will be a strong addition to the Global Leadership Team of LEO Pharma. He has an impressive track record as a global CFO from industry leading organizations and as a highly experienced strategic leader. I look very much forward to working closely with Philip as LEO Pharma goes through the next important steps of transformation,” said Christophe Bourdon, CEO of LEO Pharma.
“Joining LEO Pharma represents a unique opportunity for me to return to the healthcare industry. Also, I am excited about LEO Pharma’s transformational journey ahead supported by the joint ownership of the LEO Foundation and Nordic Capital. I look forward to meeting all my new colleagues and working together to make a real difference for people living with skin conditions,” said Philip Eickhoff.
Philip succeeds Anders Kronborg, who joined LEO Pharma in 2015. Anders has served as CFO and as Interim CEO during his time at LEO Pharma. He will retire from the company to pursue opportunities as a professional board member and advisor. Anders shared his intent to retire with the Chair of the Board of Directors in the Autumn of 2021 to ensure a timely onboarding of a suitable successor who can support LEO Pharma in achieving its long-term ambitions.
“I would like to thank Anders very much for his strong commitment to LEO Pharma over the years and his dedication to supporting the business in helping more people living with skin conditions. I wish him all the best of luck in his future endeavors”, said Christophe Bourdon.
Contacts
Media Contact
Henrik Heskjaer
hdtdk@leo-pharma.com
Director, Global External Communications
Tel: +45 3140 6180
Images
About LEO Pharma
About LEO Pharma
LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,800 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma lancerer LOQTORZI® (toripalimab) på hjemmemarkedet i Danmark7.5.2026 09:00:00 CEST | Pressemeddelelse
LOQTORZI® (toripalimab) lanceres i kombination med standardkemoterapi i Danmark som en ny førstelinjebehandling til voksne patienter med recidiverende eller metastatisk nasopharyngeal cancer, som ikke kan behandles med kirurgi eller strålebehandling (R/M NPC).¹ LOQTORZI® har vist en dokumenteret overlevelsesgevinst og kan udgøre en potentiel ny standardbehandling for patienter med fremskreden R/M NPC.² Langtidsdata fra det kliniske JUPITER-02-studie viser, at LOQTORZI® i kombination med kemoterapi giver vedvarende og signifikante forbedringer i både samlet overlevelse (OS) og progressionsfri overlevelse (PFS) sammenlignet med kemoterapi alene¹, hvilket etablerer en ny behandlingsmulighed for patienter med R/M NPC Lanceringen styrker LEO Pharmas Critical Care-portefølje på hjemmemarkedet i Danmark og demonstrerer virksomhedens engagement i at bringe nye behandlinger til patienter – via en etableret specialiseret kommerciel platform til hospitaler.
LEO Pharma delivers 9% revenue growth at CER in Q1 2026 and strengthens innovation pipeline5.5.2026 09:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 5 May, 2026 – In Q1 2026, LEO Pharma delivered robust revenue growth, driven by the dermatology portfolio, and improved profitability while significantly increasing commercial investments to support the global roll-out of Anzupgo® and the addition of Spevigo® to the portfolio. LEO Pharma also made significant strategic progress and advanced innovation through the acquisition of Replay’s next-generation gene therapy platform targeting rare genetic skin diseases, the approval of Enstilar® in China and the continued late-stage development activities for Anzupgo®, including FDA acceptance for review in adolescents with chronic hand eczema. Financial highlights LEO Pharma’s revenue increased by 4% to DKK 3,521 million, and by 9% at constant exchange rates (CER). The revenue growth was led by North America (30% at CER) and Rest of World (13% at CER), whereas sales in Europe declined by 1% at CER. Revenue from the dermatology portfolio grew by 11% (CER), driven by the strat
LEO Pharma bolsters rare skin disease focus through acquisition of Replay gene therapy platform30.4.2026 15:00:00 CEST | Pressemeddelelse
Acquisition adds high-payload herpes simplex virus (HSV) gene therapy targeting genetic skin diseases to LEO Pharma’s pipeline and further expands the company’s presence in rare dermatology Combines LEO Pharma’s six decades of dermatology expertise with Replay’s next-generation gene therapy platform to advance innovation for patients with rare skin diseases The lead program targets dystrophic epidermolysis bullosa (DEB), a devastating genetic skin disease with significant unmet medical need.
LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar®17.4.2026 09:00:00 CEST | Pressemeddelelse
NMPA approval of Enstilar® in China marks a significant milestone for LEO Pharma, expanding access to a new treatment option for the estimated 6.5 million adults living with plaque psoriasis in the world’s largest market measured by patient numbers.1 China represents a strategically important pillar in LEO Pharma’s long-term growth, and the approval strengthens the company’s position in medical dermatology by expanding its psoriasis portfolio in an exciting market for innovative treatments. Enstilar builds on LEO Pharma’s established leadership in topical psoriasis treatments, offering a clinically proven, foam-based formulation that has been widely adopted in more than 50 markets worldwide and is supported by robust phase 3 clinical data.2,3
LEO Pharma announces FDA Acceptance of supplemental NDA for ANZUPGO® (delgocitinib) cream for the treatment of Chronic Hand Eczema in children aged 12-1715.4.2026 14:00:00 CEST | Pressemeddelelse
The application is supported by positive data from the pivotal Phase 3 DELTA TEEN trial in the primary and key secondary endpoints.1 If approved, ANZUPGO will be the first treatment option specifically indicated for pediatric patients aged 12–17 living with moderate to severe chronic hand eczema (CHE).
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom